
Dexcom (($DXCM)) has held its Q3 earnings call. Read on for the main highlights of the call. Dexcom delivered a strongly positive third-quarter earnings call, marked by double-digit revenue growth,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DXCM | Dexcom | 79.32 | 19.09 | 31.70% |
| Name | Price | % Change | |
|---|---|---|---|
| $79.32 | +31.70% |

Dexcom (($DXCM)) has held its Q3 earnings call. Read on for the main highlights of the call. Dexcom delivered a strongly positive third-quarter earnings call, marked by double-digit revenue growth,

DexCom (DXCM) launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words

Dexcom (DXCM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Dexcom’s 2027 Share Repurchase Program introduces uncertainty, as management retains full discretion over timing, scale,

Notable gainers among liquid option names this morning include FedEx Freight Holding Company Inc (FDXF) $124.13 +14.44, Regeneron (REGN) $925.58 +106.81, Veralto Corp (VLTO) $113.22 +9.16, CBOE Holdings (CBOE) $332.27

JPMorgan raised the firm’s price target on DexCom (DXCM) to $85 from $82 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

Raymond James raised the firm’s price target on DexCom (DXCM) to $97 from $94 and keeps a Strong Buy rating on the shares. DexCom’s U.S. sales growth accelerated in Q3,

StoneX raised the firm’s price target on DexCom (DXCM) to $93 from $82 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

UBS raised the firm’s price target on DexCom (DXCM) to $107 from $102 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Canaccord raised the firm’s price target on DexCom (DXCM) to $97 from $90 and keeps a Buy rating on the shares. The firm updated its model following Q3 results which

Barclays raised the firm’s price target on DexCom (DXCM) to $120 from $115 and keeps an Overweight rating on the shares. The firm views the company’s Q3 report as solid.
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 18, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| hold | Assigned | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Assigned | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 11, 2027TBA | $29.91B | $0.71 | $1.38B | 0.67 | 30.63 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.